Assessment of bone related bio-markers in patients with rheumatoid arthritis treated with Certolizumab pegol

Assessment of bone related bio-markers in patients with rheumatoid arthritis treated with Certolizumab pegol - Bone related bio-markers in rheumatoid arthritis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000029594

Enrollment

Registered

2017-10-17

Start date

2017-10-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rheumatoid arthritis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Diagnosed as Rheumatoid arthritis Over 20 years old Newly administrated with Certolizumab pegol

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Clinical standardized assessments and measurement of bio-markers as below; Semaphorines 3A/3E/4A/4D/7A, Osteocarcin, Bone alkaline phosphatase (BAP), type I collagen cross-linked N-telopeptide(NTX), type I collagen cross-linked C-telopeptide(CTX),tartrate-resistant acid phosphatase(TRACP)-5b, rheumatoid factor(RF), anti-CCP antibody(ACPA), Interleukin(IL)-6, TNF arufa, IL-17	—

Secondary

Measure	Time frame
None (Observational study)	—

Countries

Japan

Contacts

Public ContactYasutaka Okita

Graduate School of Medicine, Osaka University Department of Respiratory Medicine and Clinical Immunology

y.okita@imed3.med.osaka-u.ac.jp06-6879-3833

Outcome results